These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 34088969)
1. RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma. Wang H; Wang X; Xu L; Zhang J; Cao H Sci Rep; 2021 Jun; 11(1):11836. PubMed ID: 34088969 [TBL] [Abstract][Full Text] [Related]
2. Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma. Zhang H; Zhang L; Tang Y; Wang C; Chen Y; Shu J; Zhang K Biomed Pharmacother; 2019 Oct; 118():109215. PubMed ID: 31545245 [TBL] [Abstract][Full Text] [Related]
3. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma. Wu F; Li GZ; Liu HJ; Zhao Z; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Li RP; Zhang W J Pathol; 2020 Jul; 251(3):272-283. PubMed ID: 32418210 [TBL] [Abstract][Full Text] [Related]
4. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients. Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421 [TBL] [Abstract][Full Text] [Related]
5. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009 [TBL] [Abstract][Full Text] [Related]
6. Co-amplified with PDGFRA, IGFBP7 is a prognostic biomarker correlated with the immune infiltrations of glioma. Wang H; Wang X; Xu L; Zhang J Cancer Med; 2023 Feb; 12(4):4951-4967. PubMed ID: 36043552 [TBL] [Abstract][Full Text] [Related]
7. RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping. Vergara GA; Eugenio GC; Malheiros SMF; Victor EDS; Weinlich R J Neurooncol; 2020 May; 147(3):587-594. PubMed ID: 32222932 [TBL] [Abstract][Full Text] [Related]
8. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Paul Y; Mondal B; Patil V; Somasundaram K Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842 [TBL] [Abstract][Full Text] [Related]
9. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry. Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924 [TBL] [Abstract][Full Text] [Related]
10. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas. Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770 [TBL] [Abstract][Full Text] [Related]
11. MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status. Li G; Wang Z; Zhang C; Liu X; Yang F; Sun L; Liang J; Hu H; Liu Y; You G; Bao Z; Zhang W; Wang Z; Jiang T Dis Markers; 2018; 2018():5975216. PubMed ID: 29887919 [TBL] [Abstract][Full Text] [Related]
12. IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas. Zhang L; He L; Lugano R; Roodakker K; Bergqvist M; Smits A; Dimberg A Neuro Oncol; 2018 Oct; 20(11):1505-1516. PubMed ID: 29846705 [TBL] [Abstract][Full Text] [Related]
13. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients. Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941 [TBL] [Abstract][Full Text] [Related]
14. Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma. Wu C; Song H; Fu X; Li S; Jiang T Biomed Res Int; 2020; 2020():1086792. PubMed ID: 32280672 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Immune-Related lncRNA SBF2-AS1 in Diffuse Lower-Grade Glioma. Zhang Q; Liu XJ; Li Y; Ying XW; Chen L Technol Cancer Res Treat; 2021; 20():15330338211011966. PubMed ID: 34159865 [TBL] [Abstract][Full Text] [Related]
16. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas. Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377 [TBL] [Abstract][Full Text] [Related]
17. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses. Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222 [TBL] [Abstract][Full Text] [Related]
18. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma. Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451 [TBL] [Abstract][Full Text] [Related]
19. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma. Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186 [TBL] [Abstract][Full Text] [Related]